Company Overview and News

Manila Water unit seeking to expand Boracay sewer network

2018-05-25 bworldonline
BORACAY Island Water Co., Inc. has given its assurance to complete the rehabilitation of the island’s main sewer network within four months, as the company offered its plan of upgrading and expanding the facilities as “a faster and more feasible” option.

Marikina, San Mateo, Rodriguez to experience weak water pressure

MAY 10, 2018 La Mesa Dam’s water level is reported critically low due to high demand but low supply of water. According to Manila Water, the extremely hot weather causes this predicament. INQUIRER PHOTO/ JAM STA ROSA

Crane falls, kills female septuagenarian in QC  

A 74-year-old woman died after a crane in a construction site at Barangay Old Balara, Quezon City, fell down on her Friday morning.

Ayala nets P7.7B

Conglomerate Ayala Corp. chalked up a net profit of P7.7 billion in the first quarter, 10 percent higher than the level in the previous year, led by robust earnings from its real estate and power businesses.

MWSS allays fears of water shortage in Metro Manila

La Mesa Dam’s water level is reported critically low due to high demand but low supply of water. INQUIRER PHOTO/ JAM STA ROSA

Ayala Q1 profits hit P7.7B

2018-05-11 bworldonline
THE real estate and power units of Ayala Corp. (AC) boosted its earnings for the first quarter of 2018, with net income attributable to the parent up 10% year-on-year.

Manila Water’s Rizal project to help augment dwindling supply

To address possible water interruptions due to dwindling water supply from the La Mesa Dam reservoir, water concessionaire Manila Water announced on Thursday that its Rizal Water Supply Improvement Project due to be finished this year would be tapped to augment the demand of water consumers.

Manila Water: Brace for service interruptions as La Mesa Dam hits critical level

Water concessionaire Manila Water warned on Thursday of possible service interruptions after La Mesa Dam’s water level dropped to a critical low of 72 meters.

Manila Water earnings jump 17% in 1st quarter

2018-05-09 bworldonline
AYALA-LED Manila Water Co., Inc. posted a 17% increase in first-quarter net income to P1.69 billion, with its Manila concession area mainly supporting the growth along with the expansion of its operating subsidiaries.

Manila Water net income rises 17% in Q1

2018-05-09 bworldonline
Manila Water Co., Inc. posted a 17% increase in first-quarter net income to P1.69 billion mainly coming the growth in its Manila concession area and the expansion of its operating subsidiaries.

Ayala water unit posts 17% profit growth

Manila Water Co. Inc. yesterday said its net income jumped 17 percent year-on-year in the first quarter this year to reach P1.69 billion as it saw growth across all its businesses.

Shares to decline amid weak investor sentiment

2018-05-06 bworldonline
LOCAL EQUITIES may continue to fall this week, as higher oil prices and faster inflation, among others, drag down investor sentiment.

Manila Water wins right to operate Bulacan water district

2018-05-02 bworldonline
MANILA WATER Co., Inc. has won the right to operate the Bulacan water district, which is the site of the international airport being proposed by San Miguel Corp.

Manila Water awarded Balagtas water concession deal

2018-04-26 bworldonline
LISTED Manila Water Co. Inc. said it won the auction to develop the Balagtas Water District (BWD) in Bulacan.

Ayala expanding businesses overseas

Ayala Corp. CFO Teodoro Limcaoco, chair/CEO Jaime Augusto Zobel de Ayala, president/COO Fernando Zobel de Ayala

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...